Crawford RAS, Newlands ES, Rustin GJR, et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gyaecol 1997;104:105–109.
64.
Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high risk gestational trophoblastic tumors. J Reprod Med 2002;47:465–469.
65.
Weed JC Jr, Hammond CB. Cerebral metastatic choriocarcinoma: intensive therapy and prognosis. Obstet Gynecol 1980;55:89–94.
66.
Soper JT, Spillman M, Sampson JH, et al. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. Gynecol Oncol 2007;104:691–694.
67.
Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J Reprod Med 2004;49:602– 616.
68.
Osborne R, Filiaci V, Schink J, et al. A randomized phase III trial comparing weekly parental methotrexate and pulsed dactinomycin as primary management of low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:S2.
69.
Yerandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynecol Obstet 2008;103:33–39.
70.
Osborne R, Filiaci VL, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol 2011;29:825–831.
71.
Bagshawe KD, Wilde CE. Infusion therapy for pelvic trophoblastic tumors. J Obstet Gynaecol Br Commonw 1964;71:565–570.
72.
Berkowitz RS, Goldstein DP, Bernstein MR. Ten years’ experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986;23:111–118.
73.
Curry SL, Blessing JA, DiSaia PJ, et al. A prospective randomized comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine in “poor prognosis” metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet Gynecol 1989;73:357–362.
74.
Gordon AN, Gershenson DM, Copeland LJ, et al. High-risk metastatic gestational trophoblastic disease: further stratification into clinical entities. Gynecol Oncol 1989;34:54–56.
75.
DuBeshter B, Berkowitz RS, Goldstein DP, et al. Metastatic gestational trophoblastic disease: experience at the New England